Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S2784-8671.24.07941-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies.
RMD Open
August 2025
INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.
Objective: To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related conditions of psoriatic arthritis (PsA).
Methods: This post hoc analysis primarily used data from the phase 3 KEEPsAKE 1 trial of adult patients with PsA, with data from KEEPsAKE 2 pooled for prespecified outcomes. Outcomes measuring risankizumab efficacy across key GRAPPA-recognised domains of PsA (peripheral arthritis, enthesitis, dactylitis, skin and nail psoriasis, axial disease) and PsA-related conditions such as inflammatory bowel disease (IBD) and uveitis were assessed over 100 weeks of treatment (~2 years).
A systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects.
Inflammopharmacology
August 2025
School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Background: Lichen planus (LP) is a group of chronic inflammatory disorders of the skin, mucous membranes, scalp, and nails that mainly affect the middle-aged population. Inflammatory modifiers, including interferon-α (IFN-α), IFN-γ, tumor necrosis factor-alpha (TNF-α), as well as various interleukins (ILs), such as IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12, IL-17, IL-18, IL-21, IL-22, and IL-23 has also been suggested to contribute in the LP pathogenesis. We aim to systematically evaluate the effect of IL inhibitors on treating and triggering LP disease.
View Article and Find Full Text PDFEarly response is a strong predictor of the long-term response in psoriasis patients receiving risankizumab or guselkumab in the real-world: a retrospective analysis.
Expert Rev Clin Pharmacol
June 2025
School of Medicine, Department of Dermatology and Venereology, Hacettepe University, Ankara, Turkey.
Background: Recognizing early treatment indicators that forecast the long-term effectiveness of maintenance therapy in psoriasis (PsO) could support the optimization of personalized treatments. We aimed to evaluate whether an early response can predict long-term outcomes in patients receiving risankizumab or guselkumab, and to explore the factors associated with responses.
Research Design And Methods: This retrospective study included PsO patients who received risankizumab or guselkumab continuously at least 1 year.
Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis Patients.
J Clin Med
June 2025
Rheumatology Unit, DiMePRe-J, University of Bari, 70124 Bari, Italy.
: Psoriatic arthritis (PsA) is a chronic inflammatory condition that primarily affects the musculoskeletal system and skin. While biologic and targeted synthetic DMARDs have improved treatment, many patients still fail to achieve remission. Combining conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) with biologic (b) DMARDs or targeted synthetic (ts) DMARDs shows no added benefit over monotherapy with IL-17, IL-23 inhibitors, or JAK inhibitors, unlike TNFi, which benefit from csDMARD co-administration.
View Article and Find Full Text PDFPsoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study.
Clin Exp Dermatol
August 2025
Dermatology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Background: The management of psoriasis in patients with a history of cancer remains debated, especially for the limited literature available. Given the lack of large, well-designed studies focused on this patient group, real-world clinical experiences and expert insights serve as crucial resources for guiding informed treatment decisions. This issue particularly regards the newest anti-interleukin (IL) drugs available, such as those targeting IL-23.
View Article and Find Full Text PDF